Trial Profile
Nevirapine Plasma Level After Discontinuation of Short-Term Antiretroviral Treatment for the Prevention of Mother-to-Child Transmission of HIV and Development of Drug Resistant HIV-1 Variants With 1 or 2 Weeks Continuation of Zidovudine/Lamivudine in Women After Delivery
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lamivudine/zidovudine (Primary) ; Nevirapine
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 17 Jan 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.